Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14465886 | 1.00 | CXCR3 (0.50) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL26958997 | 1.00 | CXCR3 (0.50) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL31491286 | 1.00 | CXCR3 (0.50) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL31382096 | 0.92 | CXCR3 (0.43) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL31381998 | 0.92 | CXCR3 (0.43) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL29841903 | 0.91 | MEN1 (0.42) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL29841804 | 0.91 | MEN1 (0.42) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL24674717 | 0.90 | MEN1 (0.42) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL24763856 | 0.90 | MEN1 (0.42) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 | |
| SCHEMBL24675192 | 0.89 | MEN1 (0.41) | CXCR3MEN1KMT2AGPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | SHANGHAI APEIRON THERAPEUTICS COMPANY LIMITED (CN) | 2024-05-23 | — | — | US | disclosed |
| EP-4289845-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Shanghai Apeiron Therapeutics Company Limited (CN) | 2023-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166664-A1 | TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WEE1, WEE2 | CXCR3 2010/4885MEN1 1150/4885KMT2A 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.